Latest News for: sgo

Edit

High Concordance Between Immunohistochemistry (IHC) and Next Generation Sequencing (NGS) for Determining TP53 Mutation Status in Endometrial Cancer (EC): A Post Hoc Analysis of the ENGOT EN5/GOG 3055/SIENDO Study (SGO 2025, Poster Presentation) (Karyopharm Therapeutics Inc)

Public Technologies 31 Mar 2025
). Poster #1255. Introduction. • TP53 is a well-recognized prognostic marker for EC1. • Approximately half of advanced/recurrent EC tumors are TP53 wild-type (wt)2,3 ... SIENDO. Progression-free Survival of Patients with TP53 Wild-Type EC ... Methods ... Results ... IHC.
Edit

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

PR Newswire 21 Mar 2025
(9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO) ... At this year's SGO, data ...
  • 1
×